Browse diseases

…d with METex14 subtypes was used to impute subtypes in a second NSCLC cohort with immunotherapy outcomes (N=205).Results METex14 tumo…

…Background Non-small cell lung cancer (NSCLC) frequently evades immune surveillance through defective…

…ess of consolidation. In driver-negative, immunotherapy-treated NSCLC, early phase and real-world series suggest that carefully selec…

…advances in treatments for advanced non-small cell lung cancer (NSCLC), it remains the leading cause of cancer death globally. Dozens…

…00 mg every three weeks (Q3W)) in advanced NSCLC, melanoma, and head and neck squamous cell carcinoma in both immune checkpoint inhibitor (ICI)-naive and ICI-refract…

…Int J Mol Med. 2021;48:214.Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin P…

…tion therapy.Conclusions The incidence and severity of irAEs in NSCLC patients treated with nivolumab was consistent with safety prof…

…el clinical trial ( NCT04495153), 41 patients with stage III/IV NSCLC with progressive disease despite ICI received per protocol trea…

…ted clinical activity was observed in patients with KRAS mutant NSCLC and in other solid tumors.Conclusions TNG260 in combination wit…

… NSCLC cells. For T cell suppression assays, M-MDSCs from human NSCLC were cultured with autologous T cells stimulated with anti-CD3 …

…p to November 30, 2025. Eligible studies included patients with NSCLC receiving ICIs and reported antibiotic or probiotic exposure wi…

…nce and added value to TPS.Methods Advanced stage patients with NSCLC, treated with anti-programmed cell death protein 1 ICB (±chemot…